dimethyl[(5-{[(2-{[(E)-1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}furan-2-yl)methyl]amine

• ChemBase编号: 741
• 分子式: C13H22N4O3S
• 平均质量: 314.40378
• 单一同位素质量: 314.14126158
• SMILES: S(Cc1oc(CN(C)C)cc1)CCN/C(=C/[N+](=O)[O-])/NC
• Canonical SMILES: CN/C(=C\[N+](=O)[O-])/NCCSCc1ccc(o1)CN(C)C
• InChI: InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+
• InChIKey: VMXUWOKSQNHOCA-UKTHLTGXSA-N

名称和登记号

名称

• IUPAC标准名: dimethyl[(5-{[(2-{[(E)-1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}furan-2-yl)methyl]amine
• IUPAC传统名: ranitidine.hcl
• 商标名: Alquen; Alter-H2; Alvidina; Apo-Ranitidin; Artomil; Azuranit; Coralen; Digestosan; Ergan; Esofex; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Kuracid; Label; Lake; Logat; Melfax; Microtid; Mideran; Neugal; Noctone; Noktome; Normon; Novo-Radinine; Nu-Ranit; Pep-Rani; Ptinolin; Quadrin; Quantor; RAN; Radin; Ran H2; Ran Lich; Rani 2; Rani AbZ; Rani-BASF; Rani-Puren; Rani-Q; Rani-Sanorania; Rani-nerton; Raniben; Raniberl; Raniberta; Ranibloc; Ranic; Ranicux; Ranidil; Ranidin; Ranidine; Ranidura; Ranifur; Ranigasan; Ranigast; Ranigen; Ranilonga; Ranimerck; Raniogas; Raniplex; Ranisan; Ranitab; Ranitic; Ranitidin; Ranitidin 1A Pharma; Ranitidin AL; Ranitidin AWD; Ranitidin Arcana; Ranitidin Atid; Ranitidin Basics; Ranitidin Duncan; Ranitidin Dyna; Ranitidin Helvepharm; Ranitidin Heumann; Ranitidin Hexal; Ranitidin Merck; Ranitidin Millet; Ranitidin NM; Ranitidin Normon; Ranitidin PB; Ranitidin Stada; Ranitidin von ct; Ranitidin-Cophar; Ranitidin-Isis; Ranitidin-ratiopharm; Ranitidina Tamarang; Ranitidina predilu Grif; Ranitiget; Ranitin; Ranitine; Ranobel; Rantacid; Ranuber; Raticina; Regalil; Renatac; Rozon; Rubiulcer; Santanol; Serviradine; Sostril; Tanidina; Taural; Terposen; Toriol; Trigger; Ulcecur; Ulcex; Ulcirex; Ulcodin; Ulcolind Rani; Ulsaven; Ultidine; Viserul; Zandid; Zantac; Zantac 150; Zantac 75; Zantac In Plastic Container; Zantarac; Zantic
• 别名: Ranitidine hydrochloride; Ranitidine HCL; Ranitidine Base; Rantidine HCL; Ranitidine

登记号

• CAS号: 66357-35-5
• PubChem SID: 46505543; 160964204
• PubChem CID: 657345; 3001055
• ATC码: A02BA07; A02BA02
• CHEMBL: 1790041
• Chemspider ID: 571454
• DrugBank ID: DB00863
• IUPHAR配体索引: 1234
• KEGG ID: D00422
• 美国药典/FDA物质标识码: 884KT10YB7
• 维基百科标题: Ranitidine
• Medline Plus: a601106

理论计算性质

JChem

• 质子受体: 5
• 质子供体: 2
• LogD (pH = 5.5): -1.5527394
• LogD (pH = 7.4): 0.21904218
• Log P: 0.98147845
• 摩尔折射率: 95.153 cm^3
• 极化性: 32.323387 Å^3
• 极化表面积: 86.26 Å^2
• 可自由旋转的化学键: 10
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 0.79
• LOG S: -3.6
• 溶解度: 7.95e-02 g/l

分子性质

理化性质

• 溶解度: 24.7 mg/mL
• 疏水性(logP): 1.3

药理学性质

• 给药途径: Oral, IV
• 生物利用度: 39 to 88%
• 排泄: 30–70% Renal
• 半衰期: 2–3 hours
• 代谢: Hepatic
• 蛋白结合率: 15%
• 法定药品分级: OTC (US); P/POM (UK); S2 (Australia)
• 妊娠期药物分类: B (US); B1 (Australia)
• 美国（FDA）药品许可证: Ranitidine

详细说明

DrugBank - DB00863

• Drug Groups: approved
• Description: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. [PubChem]
• Indication: Used in the treatment of peptic ulcer disease (PUD), dyspepsia, stress ulcer prophylaxis, and gastroesophageal reflux disease (GERD).
• Pharmacology: Ranitidine is a histamine H2-receptor antagonist similar to cimetidine and famotidine. An H2-receptor antagonist, often shortened to H2 antagonist, is a drug used to block the action of histamine on parietal cells in the stomach, decreasing acid production by these cells. These drugs are used in the treatment of dyspepsia, however their use has waned since the advent of the more effective proton pump inhibitors. Like the H1-antihistamines, the H2 antagonists are inverse agonists rather than true receptor antagonists.
• Toxicity: LD₅₀=77mg/kg (orally in mice). Symptoms of overdose include muscular tremors, vomiting, and rapid respiration.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic. Ranitidine is metabolized to the N-oxide, S-oxide, and N-desmethyl metabolites, accounting for approximately 4%, 1%, and 1% of the dose, respectively.
• Absorption: Approximately 50% bioavailability orally.
• Half Life: 2.8-3.1 hours
• Protein Binding: 15%
• Elimination: The principal route of excretion is the urine (active tubular excretion, renal clearance 410mL/min), with approximately 30% of the orally administered dose collected in the urine as unchanged drug in 24 hours.
• Distribution: * 1.4 L/kg; * 1.76 L/kg [clinically significant renal function impairment (creatinine clearance 25 to 35 mL/min)]
• Clearance: * 29 mL/min [clinically significant renal function impairment]; * 3 mL/min/Kg [neonatal patients]
• External Links: Wikipedia; RxList; Drugs.com